Century_PrimaryLogo_pfade_RGB_RZ.png
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 09, 2024 07:30 ET | Century Therapeutics, Inc.
- Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private...
Coherus_Logo_RGB_150.png
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
May 09, 2024 07:30 ET | Coherus BioSciences, Inc.
– New $38.7 million term loan with a May 2029 maturity –– $37.5 million royalty monetization financing based on future sales of LOQTORZI® and UDENYCA® –  REDWOOD CITY, Calif., May 09, 2024 (GLOBE...
kellylogo24.jpg
Kelly Reports First-Quarter 2024 Earnings
May 09, 2024 07:30 ET | Kelly Services, Inc.
Q1 operating earnings of $26.8 million, or up 34% on an adjusted basis Q1 revenue down following sale of European staffing operations; down 2.6% on an organic basis Q1 adjusted EBITDA margin increased...
eos_logo_2c_pri_pos_rgb_300ppi.png
Eos Energy Enterprises Announces Participation in Upcoming Investor Conferences
May 09, 2024 07:30 ET | Eos Energy Enterprises, Inc.
EDISON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. (NASDAQ: EOSE) ("Eos" or the “Company”), a leading provider of safe, scalable, efficient, and sustainable zinc-based long...
AnavexLogoR-Transparent @3x.png
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
May 09, 2024 07:30 ET | Anavex Life Sciences Corp.
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
Intellia.jpg
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 09, 2024 07:30 ET | Intellia Therapeutics, Inc.
Rapidly enrolling patients in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathyAligned with FDA on design for a new Phase 3 trial of...
Cronos-WM-Black_Logo 2 (2).jpg
Cronos Group Reports 2024 First Quarter Results
May 09, 2024 07:30 ET | Cronos Group Inc.
Industry-leading balance sheet with $855 million in cash and cash equivalents Net revenue in Q1 2024 increased by 30% year-over-year to $25.3 million Spinach® was top-3 in retail...
DXL B&T 2020.jpg
Destination XL Group, Inc. to Announce First Quarter 2024 Financial Results on May 30, 2024
May 09, 2024 07:30 ET | Destination XL Group, Inc.
CANTON, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Destination XL Group, Inc. (NASDAQ: DXLG), the leading integrated commerce retailer of Big + Tall men’s clothing and shoes, announced today it will...
1ac16241-9e05-4dc2-a463-9042c09bbcaa.jpg
SPS Commerce Acquires Traverse Systems
May 09, 2024 07:30 ET | SPS Commerce, Inc.
Acquisition expands company’s product portfolio in supply chain performance and optimization Company to host conference call today at 8:30 a.m. ET MINNEAPOLIS, May 09, 2024 (GLOBE NEWSWIRE) --...
BDTxLogo_PANTONE3135C_PNG.png
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 07:30 ET | Black Diamond Therapeutics, Inc
Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024Enrollment ongoing in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC; initial data...